AUTLAutolus LimitedInvite-only sign-up
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy · Multiple Myeloma · DLBCL · ALL, Adult and Pediatric · T Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 500 (planned)
- Started
- Aug 2, 2018
- Main results expected
- Jul 2043
- Fully finished
- Dec 2043
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy
Measured over: For up to 15 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03628612 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC